CD8A and neoplasm: In the early stage of cancer development, IL-17 may exert anti-tumor activity through different mechanisms, involving IFN-γ dependent manner and stimulating chemokines releasing from tumor cells to recruit immune cells, potentially leading to an enhanced immune response and generate more tumor-specific CD8+ cytotoxic T-lymphocytes (CTL).